Susquehanna Fundamental Investments LLC Purchases New Shares in Incyte Co. (NASDAQ:INCY)

Susquehanna Fundamental Investments LLC acquired a new position in shares of Incyte Co. (NASDAQ:INCY) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 210,237 shares of the biopharmaceutical company’s stock, valued at approximately $14,521,000.

A number of other institutional investors also recently bought and sold shares of the business. Kovitz Investment Group Partners LLC acquired a new stake in shares of Incyte during the fourth quarter worth about $305,000. Voya Investment Management LLC increased its position in Incyte by 35.7% in the 4th quarter. Voya Investment Management LLC now owns 169,697 shares of the biopharmaceutical company’s stock valued at $11,721,000 after acquiring an additional 44,688 shares during the period. Banco Bilbao Vizcaya Argentaria S.A. raised its stake in Incyte by 409.8% during the 4th quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 38,023 shares of the biopharmaceutical company’s stock valued at $2,626,000 after acquiring an additional 30,565 shares during the last quarter. Syon Capital LLC lifted its position in Incyte by 25.5% during the 4th quarter. Syon Capital LLC now owns 4,992 shares of the biopharmaceutical company’s stock worth $345,000 after acquiring an additional 1,015 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Incyte by 50.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 913,708 shares of the biopharmaceutical company’s stock valued at $63,111,000 after purchasing an additional 305,264 shares during the last quarter. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Sheila A. Denton sold 14,069 shares of the company’s stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $74.07, for a total transaction of $1,042,090.83. Following the transaction, the executive vice president now owns 25,848 shares of the company’s stock, valued at approximately $1,914,561.36. This represents a 35.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Barry P. Flannelly sold 19,807 shares of the firm’s stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $67.69, for a total transaction of $1,340,735.83. Following the sale, the executive vice president now owns 33,567 shares in the company, valued at approximately $2,272,150.23. This trade represents a 37.11 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,475 shares of company stock worth $2,424,751. 17.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Truist Financial cut their price target on Incyte from $74.00 to $72.00 and set a “hold” rating for the company in a research note on Tuesday, March 18th. Guggenheim downgraded shares of Incyte from a “buy” rating to a “neutral” rating and set a $92.00 price objective for the company. in a research report on Tuesday, March 18th. William Blair downgraded shares of Incyte from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 18th. Stifel Nicolaus increased their price target on shares of Incyte from $75.00 to $77.00 and gave the stock a “hold” rating in a report on Monday, February 10th. Finally, Royal Bank of Canada lowered their price objective on Incyte from $70.00 to $68.00 and set a “sector perform” rating on the stock in a report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $74.69.

Incyte Trading Up 0.3 %

Shares of INCY opened at $59.16 on Friday. Incyte Co. has a 1-year low of $50.35 and a 1-year high of $83.95. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.97 and a quick ratio of 1.94. The firm has a 50 day simple moving average of $63.63 and a 200-day simple moving average of $69.02. The stock has a market cap of $11.45 billion, a price-to-earnings ratio of 219.12, a price-to-earnings-growth ratio of 0.41 and a beta of 0.89.

Incyte (NASDAQ:INCY) last released its quarterly earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%. Equities analysts forecast that Incyte Co. will post 4.86 EPS for the current fiscal year.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.